Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics

Virginia Corbett; Paul Hallenbeck; Piotr Rychahou; Aman Chauhan

doi:10.3389/fmolb.2022.930207

Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics

Front Mol Biosci. 2022 Aug 26:9:930207. doi: 10.3389/fmolb.2022.930207. eCollection 2022.

Authors

Virginia Corbett¹, Paul Hallenbeck², Piotr Rychahou³, Aman Chauhan⁴

Affiliations

¹ Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
² Seneca Therapeutics, Inc., Blue Bell, PA, United States.
³ Department of Surgery, Markey Cancer Center, University of Kentucky, Lexington, KY, United States.
⁴ Division of Medical Oncology, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, United States.

Abstract

Oncolytic viruses have made a significant inroad in cancer drug development. Numerous clinical trials are currently investigating oncolytic viruses both as single agents or in combination with various immunomodulators. Oncolytic viruses (OV) are an integral pillar of immuno-oncology and hold potential for not only delivering durable anti-tumor responses but also converting "cold" tumors to "hot" tumors. In this review we will discuss one such promising oncolytic virus called Seneca Valley Virus (SVV-001) and its therapeutic implications. SVV development has seen seismic evolution over the past decade and now boasts of being the only OV with a practically applicable biomarker for viral tropism. We discuss relevant preclinical and clinical data involving SVV and how bio-selecting for TEM8/ANTXR1, a negative tumor prognosticator can lead to first of its kind biomarker driven oncolytic viral cancer therapy.

Keywords: TEM8/ANTXR1; drug development; neuroendocrine carcinomas; neuroendocrine tumors; oncolytic virus; seneca valley virus; solid tumors.

Publication types

Review